Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the sale, the chief executive officer directly owned 2,175,000 shares in the company, valued at $190,334,250. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

iRadimed stock traded up $3.04 during midday trading on Wednesday, reaching $90.40. 169,288 shares of the stock were exchanged, compared to its average volume of 90,268. The company’s fifty day moving average is $93.22 and its 200-day moving average is $94.91. The firm has a market cap of $1.16 billion, a PE ratio of 49.40 and a beta of 0.90. iRadimed Corporation has a 52 week low of $50.88 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is presently 43.72%.

Institutional Investors Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in IRMD. SG Americas Securities LLC boosted its position in iRadimed by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Principal Financial Group Inc. purchased a new stake in iRadimed during the 3rd quarter valued at $422,000. Tudor Investment Corp ET AL purchased a new stake in iRadimed during the 3rd quarter valued at $666,000. Baader Bank Aktiengesellschaft purchased a new stake in iRadimed during the 4th quarter valued at $595,000. Finally, RFG Advisory LLC purchased a new stake in shares of iRadimed in the 4th quarter worth about $1,594,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of research analyst reports. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings raised shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Roth Mkm reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Finally, Lake Street Capital reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.